Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.28
ACT's Cash-to-Debt is ranked lower than
79% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. ACT: 0.28 )
Ranked among companies with meaningful Cash-to-Debt only.
ACT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.68 Max: N/A
Current: 0.28
Equity-to-Asset 0.59
ACT's Equity-to-Asset is ranked lower than
57% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ACT: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
ACT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.64 Max: 0.93
Current: 0.59
0.25
0.93
Piotroski F-Score: 8
Altman Z-Score: 1.16
Beneish M-Score: -2.03
WACC vs ROIC
6.42%
-1.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -17.36
ACT's Operating Margin % is ranked lower than
79% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. ACT: -17.36 )
Ranked among companies with meaningful Operating Margin % only.
ACT' s Operating Margin % Range Over the Past 10 Years
Min: -54.9  Med: 6.95 Max: 14.13
Current: -17.36
-54.9
14.13
Net Margin % 82.42
ACT's Net Margin % is ranked higher than
99% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. ACT: 82.42 )
Ranked among companies with meaningful Net Margin % only.
ACT' s Net Margin % Range Over the Past 10 Years
Min: -34.87  Med: 5.67 Max: 102.76
Current: 82.42
-34.87
102.76
ROE % 15.02
ACT's ROE % is ranked higher than
73% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. ACT: 15.02 )
Ranked among companies with meaningful ROE % only.
ACT' s ROE % Range Over the Past 10 Years
Min: -11.23  Med: 7.32 Max: 19.24
Current: 15.02
-11.23
19.24
ROA % 9.09
ACT's ROA % is ranked higher than
75% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. ACT: 9.09 )
Ranked among companies with meaningful ROA % only.
ACT' s ROA % Range Over the Past 10 Years
Min: -4.32  Med: 4.03 Max: 11.32
Current: 9.09
-4.32
11.32
ROC (Joel Greenblatt) % -181.03
ACT's ROC (Joel Greenblatt) % is ranked lower than
85% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.97 vs. ACT: -181.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -181.03  Med: 20.42 Max: 38.44
Current: -181.03
-181.03
38.44
3-Year Revenue Growth Rate 27.40
ACT's 3-Year Revenue Growth Rate is ranked higher than
90% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. ACT: 27.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.3  Med: 17.5 Max: 40.4
Current: 27.4
-16.3
40.4
3-Year EBITDA Growth Rate 41.70
ACT's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. ACT: 41.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.7  Med: 13.1 Max: 67.4
Current: 41.7
-47.7
67.4
3-Year EPS without NRI Growth Rate -1.20
ACT's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. ACT: -1.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.1  Med: 5.4 Max: 94.3
Current: -1.2
-27.1
94.3
GuruFocus has detected 3 Warning Signs with Allergan PLC $ACT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACT's 30-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA867.696.345 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:TKPYY, NYSE:TEVA, NYSE:ZTS, NAS:MYL, OTCPK:SGIOY, OTCPK:ESALY, OTCPK:MKGAY, OTCPK:MTZPY, OTCPK:IPSEY, OTCPK:HLUYY, NYSE:PRGO, OTCPK:APNHY, NYSE:RDY, OTCPK:GZPHY, OTCPK:HYPMY, NYSE:PTHN, OTCPK:HKMPF, NYSE:CTLT, NYSE:TARO, NYSE:VRX » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Headquarter Location:Ireland
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Allergan is one of the largest specialty pharmaceutical manufacturers. Allergan specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.

Top Ranked Articles about Allergan PLC

FDA to Examine Amgen's ABP 215 Drug is a biosimilar candidate to a medication for the treatment of various forms of tumors
Amgen Inc. (NASDAQ:AMGN) informed the market June 7 through the PR Newswire that the members of the Food and Drug Administration’s Oncologic Drugs Advisory Committee will get together on July 13 to examine Amgen's Biologics License Application (BLA). Read more...
The Fading Fortunes of John Paulson Hedge fund guru won attention for his strategy during the subprime crisis, but lately he’s been getting attention for the wrong reasons
John Paulson (Trades, Portfolio) was once a darling of Wall Street, having handsomely profited because of his smart bets on the subprime crisis while many of his counterparts suffered. Read more...
Wallace Weitz Sells Avon Products, Berkshire Hathaway, Fossil Guru's largest 1st-quarter sales
Wallace Weitz (Trades, Portfolio) manages a portfolio composed of 81 stocks with a total value of $2.383 billion. During the first quarter the guru sold shares in the following stocks. Read more...
Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab
Allergan to Acquire Keller Medical, Inc., Adding Keller Funnel® to Company's Leading Plastic Surgery Portfolio
Allergan to Present New Data on Chronic Migraine at the American Headache Society Meeting in Boston
Allergan to Present at the Goldman Sachs Global Healthcare Conference
Allergan Announces Closing of Public Offering of Senior Notes to Refinance Existing Debt
Allergan Announces Pricing of Tender Offers by Certain Subsidiaries
Allergan Announces Early Tender Results and Upsizing of Tender Offers by Certain Subsidiaries

Ratios

vs
industry
vs
history
PE Ratio 8.14
ACT's PE Ratio is ranked higher than
93% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.12 vs. ACT: 8.14 )
Ranked among companies with meaningful PE Ratio only.
ACT' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 23.77 Max: 366.63
Current: 8.14
4.95
366.63
Forward PE Ratio 14.86
ACT's Forward PE Ratio is ranked higher than
71% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.73 vs. ACT: 14.86 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 5.02
ACT's Price-to-Owner-Earnings is ranked higher than
94% of the 305 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.72 vs. ACT: 5.02 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ACT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.54  Med: 18.17 Max: 1421.16
Current: 5.02
3.54
1421.16
PB Ratio 1.17
ACT's PB Ratio is ranked higher than
85% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. ACT: 1.17 )
Ranked among companies with meaningful PB Ratio only.
ACT' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.74 Max: 5.9
Current: 1.17
0.87
5.9
PS Ratio 6.10
ACT's PS Ratio is ranked lower than
70% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ACT: 6.10 )
Ranked among companies with meaningful PS Ratio only.
ACT' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 1.86 Max: 13.79
Current: 6.1
0.99
13.79
Price-to-Free-Cash-Flow 319.05
ACT's Price-to-Free-Cash-Flow is ranked lower than
93% of the 210 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.65 vs. ACT: 319.05 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.64  Med: 16.09 Max: 320.67
Current: 319.05
6.64
320.67
Price-to-Operating-Cash-Flow 95.88
ACT's Price-to-Operating-Cash-Flow is ranked lower than
90% of the 284 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.79 vs. ACT: 95.88 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.99  Med: 12.96 Max: 96.36
Current: 95.88
5.99
96.36
EV-to-EBIT -26.32
ACT's EV-to-EBIT is ranked lower than
99.99% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.94 vs. ACT: -26.32 )
Ranked among companies with meaningful EV-to-EBIT only.
ACT' s EV-to-EBIT Range Over the Past 10 Years
Min: -310.4  Med: 10.25 Max: 104.6
Current: -26.32
-310.4
104.6
EV-to-EBITDA 42.20
ACT's EV-to-EBITDA is ranked lower than
83% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.60 vs. ACT: 42.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 12.3 Max: 589.4
Current: 42.2
-224.1
589.4
Shiller PE Ratio 63.47
ACT's Shiller PE Ratio is ranked lower than
68% of the 196 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.28 vs. ACT: 63.47 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.19  Med: 52.78 Max: 2307.73
Current: 63.47
14.19
2307.73
Current Ratio 1.32
ACT's Current Ratio is ranked lower than
79% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. ACT: 1.32 )
Ranked among companies with meaningful Current Ratio only.
ACT' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.96 Max: 9.8
Current: 1.32
0.99
9.8
Quick Ratio 1.23
ACT's Quick Ratio is ranked lower than
67% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. ACT: 1.23 )
Ranked among companies with meaningful Quick Ratio only.
ACT' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 2.1 Max: 8.82
Current: 1.23
0.78
8.82
Days Inventory 162.31
ACT's Days Inventory is ranked lower than
72% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.03 vs. ACT: 162.31 )
Ranked among companies with meaningful Days Inventory only.
ACT' s Days Inventory Range Over the Past 10 Years
Min: 108.11  Med: 126.6 Max: 369.82
Current: 162.31
108.11
369.82
Days Sales Outstanding 62.93
ACT's Days Sales Outstanding is ranked higher than
61% of the 655 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. ACT: 62.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 65.51 Max: 197.04
Current: 62.93
39.05
197.04
Days Payable 58.16
ACT's Days Payable is ranked lower than
59% of the 603 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.27 vs. ACT: 58.16 )
Ranked among companies with meaningful Days Payable only.
ACT' s Days Payable Range Over the Past 10 Years
Min: 28.64  Med: 69.22 Max: 109.48
Current: 58.16
28.64
109.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.30
ACT's 3-Year Average Share Buyback Ratio is ranked lower than
85% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. ACT: -24.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6.7 Max: 2
Current: -24.3
-45.6
2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.10
ACT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
82% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. ACT: 1.10 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.23 Max: 4.58
Current: 1.1
0.59
4.58
Price-to-Median-PS-Value 3.28
ACT's Price-to-Median-PS-Value is ranked lower than
93% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. ACT: 3.28 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.66  Med: 2.02 Max: 6.61
Current: 3.28
0.66
6.61
Earnings Yield (Greenblatt) % -3.80
ACT's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.98 vs. ACT: -3.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10.5  Med: 2.1 Max: 12.3
Current: -3.8
-10.5
12.3
Forward Rate of Return (Yacktman) % 6.98
ACT's Forward Rate of Return (Yacktman) % is ranked lower than
57% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.09 vs. ACT: 6.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8  Med: 7.1 Max: 16.1
Current: 6.98
-8
16.1

More Statistics

Short Percentage of Float1.14%
52-Week Range $201.91 - 317.72
Shares Outstanding (Mil)392.44
» More Articles for ACT

Headlines

Articles On GuruFocus.com
FDA to Examine Amgen's ABP 215 Jun 08 2017 
The Fading Fortunes of John Paulson Jun 08 2017 
Wallace Weitz Sells Avon Products, Berkshire Hathaway, Fossil Jun 07 2017 
Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate Jun 07 2017 
Allergan to Acquire Keller Medical, Inc., Adding Keller Funnel® to Company's Leading Plastic Surger Jun 07 2017 
Allergan to Present New Data on Chronic Migraine at the American Headache Society Meeting in Boston Jun 07 2017 
Allergan to Present at the Goldman Sachs Global Healthcare Conference Jun 02 2017 
Allergan Announces Closing of Public Offering of Senior Notes to Refinance Existing Debt May 26 2017 
Allergan Announces Pricing of Tender Offers by Certain Subsidiaries May 24 2017 
Allergan Announces Early Tender Results and Upsizing of Tender Offers by Certain Subsidiaries May 24 2017 

More From Other Websites
Valeant and Actavis agree to stay litigation relating to Valeant's top-selling drug Xifaxan May 17 2017
Teva Q1 profit tops estimates, revenue up on Actavis deal May 11 2017
Allergan posts loss as it writes down Teva holdings May 09 2017
Bill Ackman's Insider Trading Lawsuit May Cost Pershing Square Investors $75 Million Mar 29 2017
Risk-Reward With Teva Pharmaceutical Mar 27 2017
Court allows Allergan shareholders to go after Ackman, Valeant as a class Mar 16 2017
Allergan plc Question if a Feminist Can Love Fillers? Mar 09 2017
Billionaires Love These 3 Healthcare Stocks Mar 05 2017
Allergan CEO Pushes for Trump to Lead Drug Price Discussions Feb 22 2017
Allergan CEO: Gov’t taking over drug pricing is last thing we need Feb 22 2017
Allergan CEO: I don’t know if we’d relocate after tax reform Feb 22 2017
Hologic Follows Allergan, Buying Body-Sculptor Cynosure For $1.65 Bil Feb 14 2017
Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13% Feb 13 2017
Why Chemours, Zeltiq Aesthetics, and Vale Jumped Today Feb 13 2017
Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 bln Feb 13 2017
Allergan Shares Surge After Announcing Acquisition of Zeltiq Aesthetics Feb 13 2017
Teva seeks CEO with pharma background to lead recovery efforts Feb 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}